AOD-9604

TB-500 10mg Research Peptide UK

TB-500 10mg is one of the most widely studied recovery research peptides available to UK laboratories. Also known as Thymosin Beta-4 Fragment (Ac-LKKTETQ), it is a synthetic heptapeptide corresponding to amino acids 17 to 23 of Thymosin Beta-4 — specifically the actin-binding domain of the naturally occurring TMSB4X gene protein. With a molecular formula of C38H68N10O14 and a molecular weight of 889.02 g/mol, the tb 500 10mg research peptide is a well-characterised compound supported by a substantial body of published preclinical literature.

The primary mechanism of TB-500 10mg in laboratory cell models involves binding to globular actin (G-actin), sequestering monomeric actin and modulating the equilibrium between G-actin and filamentous F-actin. This cytoskeletal modulation has downstream effects on cell shape, mechanical properties, and directed cell motility in published research models. Laboratory studies have also documented TB-500 activity in scratch assay migration models, collagen deposition assays, and NF-kB inflammatory pathway research.

The 10mg format of this tb 500 research peptide provides the compound volume needed for full dose-response gradient studies, multi-arm experimental designs, and extended single-batch longitudinal programmes where batch consistency is critical for reproducibility.

TB-500 10mg and BPC-157 10mg are the two most widely studied recovery research peptides in the UK market. They are mechanistically complementary rather than identical — TB-500 operates through actin-binding and cytoskeletal dynamics, while BPC-157 acts primarily through the nitric oxide (NO) and VEGF pathways. These distinct mechanisms allow both compounds to be used as independent variables within the same experimental protocol. For a full mechanistic comparison of these two recovery peptides, researchers can consult the TB-500 10mg research guide published on the Ascend Peptides UK blog.

Every batch of TB-500 10mg from Ascend Peptides UK is independently tested by Janoshik, a specialist external analytical laboratory. HPLC purity is confirmed at greater than or equal to 98%, and LC-MS analysis confirms the molecular identity at C38H68N10O14 and 889.02 g/mol. The full Certificate of Analysis for each batch is publicly verifiable at janoshik.com.

For reconstitution, add BP-grade bacteriostatic water slowly down the inner vial wall, gently swirl to dissolve, and aliquot immediately into single-use volumes. Store lyophilised powder at minus 20°C. Avoid freeze-thaw cycles. Bacteriostatic water for research is available separately from Ascend Peptides UK.

WADA Status: TB-500 is listed on the WADA Prohibited List as a non-Specified Substance, prohibited at all times. UK athletes subject to UKAD regulations must not use this compound.

DISCLAIMER: For in-vitro laboratory research only. Not for human consumption, therapeutic, diagnostic, or clinical use. Not classified as a medicinal product for therapeutic, clinical or dianostic use by the MHRA.